- Home
- LSTA vs PRTG Comparison
LSTA vs PRTG Comparison
Compare LSTA & PRTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSTA
- PRTG
- Stock Information
- Founded
- LSTA 1980
- PRTG 1973
- Country
- LSTA United States
- PRTG British Virgin Islands
- Employees
- LSTA N/A
- PRTG N/A
- Industry
- LSTA Misc Health and Biotechnology Services
- PRTG Oil & Gas Production
- Sector
- LSTA Health Care
- PRTG Energy
- Exchange
- LSTA Nasdaq
- PRTG Nasdaq
- Market Cap
- LSTA 20.0M
- PRTG 17.7M
- IPO Year
- LSTA N/A
- PRTG N/A
- Fundamental
- Price
- LSTA $2.69
- PRTG $8.41
- Analyst Decision
- LSTA Strong Buy
- PRTG
- Analyst Count
- LSTA 1
- PRTG 0
- Target Price
- LSTA $15.00
- PRTG N/A
- AVG Volume (30 Days)
- LSTA 15.4K
- PRTG 30.8K
- Earning Date
- LSTA 05-08-2025
- PRTG 06-17-2025
- Dividend Yield
- LSTA N/A
- PRTG N/A
- EPS Growth
- LSTA N/A
- PRTG N/A
- EPS
- LSTA N/A
- PRTG N/A
- Revenue
- LSTA $1,000,000.00
- PRTG N/A
- Revenue This Year
- LSTA N/A
- PRTG N/A
- Revenue Next Year
- LSTA N/A
- PRTG N/A
- P/E Ratio
- LSTA N/A
- PRTG N/A
- Revenue Growth
- LSTA N/A
- PRTG N/A
- 52 Week Low
- LSTA $1.87
- PRTG $2.10
- 52 Week High
- LSTA $4.20
- PRTG $23.01
- Technical
- Relative Strength Index (RSI)
- LSTA 57.86
- PRTG 52.50
- Support Level
- LSTA $2.59
- PRTG $7.51
- Resistance Level
- LSTA $2.80
- PRTG $8.77
- Average True Range (ATR)
- LSTA 0.19
- PRTG 0.64
- MACD
- LSTA 0.00
- PRTG 0.01
- Stochastic Oscillator
- LSTA 59.09
- PRTG 70.18
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively.
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.